Bristol Myers Squibb (BMY)

Bristol Myers Squibb (BMY-N) has received mixed reviews from experts, indicating potential strengths in its drug pipeline and dividends but also raising concerns about disappointing sales in certain areas, particularly regarding its Cobenfy drug. Some experts emphasize the company's growth portfolio, which has shown an impressive 18% year-over-year increase, while others voice caution due to declining sales from its legacy drugs. Despite some hesitations, recent earnings results exceeded expectations, with EPS and sales both surpassing estimates, leading to a raised revenue guidance for 2025. The sentiment suggests that the stock may have a chance to rebound if newer products continue to outperform older ones, though individual opinions vary significantly, highlighting a diversity of perspectives on the future performance of the stock.